

Urethral Obstruction

Urethral obstruction is a life-threatening form of feline lower urinary tract disease. Reported rates of re-obstruction range from 14.8% to 36%. The medical records of 87 cats with acute urethral obstructions and abdominal ultrasound (US) performed within the first 24 hours of hospitalization were reviewed. Only cats with no cystocentesis prior to US were included. The goals were to describe the post-obstruction urinary tract ultrasound findings and determine any associations with re-obstruction, clinicopathologic findings, and length of hospitalization.

The most common US findings of the bladder included echogenic urinary sediment and increased urinary echoes, bladder wall thickening, pericystic effusion, and hyperechoic pericystic fat. For the kidneys and ureters, the most common findings included pyelectasia, renomegaly, perirenal effusion, hyperechoic perirenal fat, and ureteral dilation. Urethral findings were not recorded as all cats had indwelling urethral catheters at the time of US. Cystolithiasis was found in 47.1 % of all cats. Perirenal effusion was associated with hyperkalemia. Eighty-two of 87 cats survived to discharge. A six-month follow-up was available for 61 medically treated cats and 21/61 (34.4%) had

re-obstructed (13/21 within 14 days of discharge). None of the US findings were predictive for re-obstruction.

Commentary

Although radiographs are commonly performed in cats with urethral obstruction to evaluate for calculi and confirm position of a urinary catheter, the use of US may provide additional information in regard to the genitourinary tract that may aid management decisions. This study documents both anticipated abnormalities (eg, echogenic urine sediment) and some unexpected abnormalities (eg, intraluminal septa). Although medical management is effective in many cases, hospitalization and treatment for urethral obstruction can be relatively expensive, and clients may need to weigh the costs of surgical management (both financial and risks) if warranted vs the risk of re-obstruction and cost of recurrent in-hospital medical management. Although this study did not find an association between these abnormalities and an increased risk for re-obstruction, further prospective studies are needed to evaluate the use of ultrasonography in facilitating clinical management of cats with urethral obstructions and risks for re-obstruction.—Tara J. Fetzer, DVM

Source

Nevins JR, Mai W, Thomas E. Associations between ultrasound and clinical findings in 87 cats with urethral obstruction. *Vet Radiol Ultrasound*. 2015;56(4):439-447.

Further prospective studies are needed to evaluate the use of ultrasonography in facilitating clinical management of cats with urethral obstructions and risks for re-obstruction.



(florfenicol, terbinafine, mometasone furoate)

Otic Solution

Antibacterial, antifungal, and anti-inflammatory
For Otic Use in Dogs Only

The following information is a summary of the complete product information and is not comprehensive. Please refer to the approved product label for complete product information prior to use.

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

PRODUCT DESCRIPTION: CLARO™ contains 15.0 mg/mL florfenicol, 13.3 mg/mL terbinafine (equivalent to 15.0 mg/mL terbinafine hydrochloride) and 2.0 mg/mL mometasone furoate. Inactive ingredients include purified water, propylene carbonate, propylene glycol, ethyl alcohol, and polyethylene glycol.

INDICATIONS:

CLARO™ is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (*Malassezia pachydermatis*) and bacteria (*Staphylococcus pseudintermedius*).

DOSAGE AND ADMINISTRATION:

CLARO™ should be administered by veterinary personnel. Administration is one dose (1 dropperette) per affected ear. The duration of effect should last 30 days. Clean and dry the external ear canal before administering the product. Verify the tympanic membrane is intact prior to administration. Cleaning the ear after dosing may affect product effectiveness. Refer to product label for complete directions for use.

CONTRAINDICATIONS:

Do not use in dogs with known tympanic membrane perforation (see **PRECAUTIONS**).

CLARO™ is contraindicated in dogs with known or suspected hypersensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate, the inactive ingredients listed above, or similar drugs, or any ingredient in these medicines.

WARNINGS:

Human Warnings: Not for use in humans. Keep this and all drugs out of reach of children. In case of accidental ingestion by humans, contact a physician immediately. In case of accidental skin contact, wash area thoroughly with water. Avoid contact with eyes. Humans with known hypersensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate should not handle this product.

PRECAUTIONS:

Do not administer orally.

The use of CLARO™ in dogs with perforated tympanic membranes has not been evaluated. The integrity of the tympanic membrane should be confirmed before administering the product. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment.

Use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs.

Use with caution in dogs with impaired hepatic function. The safe use of CLARO™ in dogs used for breeding purposes, during pregnancy, or in lactating bitches has not been evaluated.

ADVERSE REACTIONS:

In a field study conducted in the United States, there were no directly attributable adverse reactions in 146 dogs administered CLARO™. To report suspected adverse drug events and/or obtain a copy of the Safety Data Sheet (SDS) or for technical assistance, contact Bayer HealthCare at 1-800-422-9874.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>.

Bayer

Bayer (reg'd), the Bayer Cross (reg'd) and CLARO™ are trademarks of Bayer.
©2015 Bayer HealthCare LLC.
Distributed by: Bayer HealthCare LLC Animal Health Division Shawnee Mission, Kansas 66201 USA NADA 141-440, Approved by FDA.